MIDEA-INDUSTRIAL-TECH
14.7.2022 04:16:12 CEST | Business Wire | Press release
Motinova’s and Welling’s latest E-bike motor series debut at EUROBIKE 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005981/en/
By 2030, the global E-Bike market will reach 19 million units. As the green and low-carbon lifestyle trends, E-bikes have gradually become an alternative choice for urban commuters and field riders. Welling and Motinova offer three central motors for large chain wheels: Welling W6000, Welling 8500, and Motinova MT6000, featuring higher power density, higher efficiency, shorter response time, and lower wastage rate.
Welling W6000 for urban E-bikes: This high-performing central motor for large chain wheels is compact and low-noise designed (under 52dB), enabling a quiet riding experience. Its innovative torque sensor can adapt to a highly flexible riding curve for different biking scenarios. Its algorithm allows high-precision delay and inertia compensation for a smoother and more stable riding experience.
Welling W8500 for mountain E-bikes: Its unique flat wire winding structure with optimized design can enable efficiency to reach 80%, and increase battery range in mountain biking. Its ultra-high overload capacity can run continuously at 75% peak torque while keeping the shell temperature below 60°C for longer service life and more powerful output. Its highly integrated design enables it to have a weight of less than 3 kg in a very compact size.
Motinova MT6000: This high-performing central motor for large chain wheels is designed for urban commuters. The motor is only 3 kg and is very delicate. It could provide a maximum assistance rate of 270% in a strong and quiet momentum. Its pedaling rate can reach as high as 100rpm with five riding modes. Bikers can enjoy the fun of riding in all kinds of road conditions.
Motinova motors for small chain wheels, such as the VOLANS and PEGASI series; cycle computers; accessories; and other biking offerings are also on exhibition. In the outdoor exhibition area, Motinova and Welling also provide a fun test riding experience, “Ride Longer, Live Better.”
Motinova and Welling will further enhance their core capabilities in the field of intelligent transportation and the two-wheel transportation market.
Motinova’s and Welling’s parent, Midea Industrial Technology, has built 27 R&D centers in China, Austria, India, and Japan, with an accumulation of more than 5,500 authorized patents.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005981/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom